A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma

Currently, sorafenib-based therapy is the standard treatment for advanced hepatocellular carcinoma (HCC), and there is a strong rationale for investigating its use in combination with other agents to achieve better therapeutic effects. Aurora-A, a member of a family of mitotic serine/threonine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kai, Wang, Ting, Zhou, Hao, Feng, Bing, Chen, Ying, Zhi, Yingru, Wang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172479/
https://www.ncbi.nlm.nih.gov/pubmed/30292139
http://dx.doi.org/10.1016/j.omtn.2018.08.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172479/
https://www.ncbi.nlm.nih.gov/pubmed/30292139
http://dx.doi.org/10.1016/j.omtn.2018.08.014

Ejemplares similares